Syntekabio Completes Construction of Own AI Bio Supercomputing Center in Daejeon Dungok

AI drug development specialist Syntekabio announced on the 5th that it has obtained the usage approval for the AI Bio Supercom (ABS) Center, established within the Dungok District, a hub area of the Daejeon International Science Business Belt.

The Syntekabio ABS Center was completed as a four-story building with a total floor area of 3,954.54㎡ and a building area of 1,387.39㎡ on a research site of 10,200㎡ (approximately 3,000 pyeong) in the Dungok District of Daejeon. After completing the relocation of supercomputing equipment previously housed at the Guro Center, the equipment will resume operation and stabilization, with full-scale operation scheduled for the end of October.

The ABS Center aims for eco-friendliness and high efficiency by applying a natural convection heat dissipation design based on a "termite mound structure." The Power Usage Effectiveness (PUE), an energy efficiency metric for data centers calculated by dividing the actual annual power consumption by the required power, indicates better energy efficiency the closer it is to 1. Syntekabio plans to maximize energy efficiency at the ABS Center by setting a PUE target of approximately 1.1.

The center applies inert gas fire extinguishing equipment in accordance with the Fire Safety Standards (NFSC 107A) announced by the Fire Agency Notification No. 2022-41 (November 25, 2022). This system uses gases harmless to humans, ensuring safety. Additionally, the fire safety equipment is divided into six zones, allowing the data center to operate normally even if a specific sector is unavailable.

Starting from the activation of the ABS Center, the company plans to strengthen its existing one-stop service using DeepMatcher (DDC service) and modularize key platforms and services to launch them as Software as a Service (SaaS). The SaaS model is expected to be released early next year, with subscription-based pricing allowing clients to use services starting from $1,000 annually according to their needs.

Jung Jong-sun, CEO of Syntekabio, said, “We are very pleased to have completed the ABS Center, focusing on eco-friendliness, high energy efficiency, and safety without major issues. The ABS Center and infrastructure we have built will be a crucial foundation not only for advancing our AI drug platform but also for contracting with domestic and international pharmaceutical companies and supplying services.”

He added, “With the completion of the ABS Center laying the groundwork for global business, we will successfully conclude ongoing business deals and aim to show tangible results as soon as possible.”

This content was produced with the assistance of AI translation services.